Sally Bell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sally Bell has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Miles Patrick Sparrow
Alfred Health and Monash University
8 shared publications - Jane M. Andrews
Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, South Australia, Australia
7 shared publications - Peter A. Bampton
Department of Gastroenterology and Hepatology, Flinders Medical Centre, South Australia, Australia; Flinders University of South Australia, Australia
7 shared publications - Susan J. Connor
Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, Australia
7 shared publications - Amy L. Hamilton
Department of Gastroenterology, St Vincent’s Hospital, Melbourne 3065, Australia
4 shared publications - Graham L. Radford-Smith
Gastroenterology and Hepatology Department Inflammatory Bowel Disease Unit Royal Brisbane and Women's Hospital Brisbane Australia
4 shared publications
Latest Publications
- 24 March 2019
- Published by AMPCo in Medical Journal of Australia
- Vol. 210 (6) , 276-280
Updates in the management of inflammatory bowel disease during pregnancy
The best pregnancy outcomes for women with inflammatory bowel disease (IBD) occur when their disease is in remission at conception and remains in remission throughout pregnancy. Active IBD can lead to adverse pregnancy outcomes, including spontaneous abortion, pre‐term birth and low birthweight. The majority of women with IBD who are taking maintenance medication will require medication throughout the pregnancy to prevent disease relapse. Most IBD medications are considered safe in pregnancy and breastfeeding, except for methotrexate. Pre‐conception counselling should be arranged with the patient's IBD specialist and should include discussions regarding the importance of optimising disease control before and during pregnancy as well as the medication management plan for pregnancy. Patients with IBD should be reassured that their fertility is normal when the disease is quiescent, with the exception of women who have had pelvic surgery. IBD activity should be carefully monitored during pregnancy using non‐invasive techniques, and disease flares during pregnancy should be treated promptly with escalation of therapy in consultation with the patient's IBD specialist. Mode of delivery should be determined by obstetric need; however, caesarean delivery is preferred for women with a history of ileal pouch anal anastomosis surgery or active perianal Crohn's disease.
- 24 March 2019
- Published by AMPCo in Medical Journal of Australia
- Vol. 210 (6) , 276-280
Updates in the management of inflammatory bowel disease during pregnancy
The best pregnancy outcomes for women with inflammatory bowel disease (IBD) occur when their disease is in remission at conception and remains in remission throughout pregnancy. Active IBD can lead to adverse pregnancy outcomes, including spontaneous abortion, pre‐term birth and low birthweight. The majority of women with IBD who are taking maintenance medication will require medication throughout the pregnancy to prevent disease relapse. Most IBD medications are considered safe in pregnancy and breastfeeding, except for methotrexate. Pre‐conception counselling should be arranged with the patient's IBD specialist and should include discussions regarding the importance of optimising disease control before and during pregnancy as well as the medication management plan for pregnancy. Patients with IBD should be reassured that their fertility is normal when the disease is quiescent, with the exception of women who have had pelvic surgery. IBD activity should be carefully monitored during pregnancy using non‐invasive techniques, and disease flares during pregnancy should be treated promptly with escalation of therapy in consultation with the patient's IBD specialist. Mode of delivery should be determined by obstetric need; however, caesarean delivery is preferred for women with a history of ileal pouch anal anastomosis surgery or active perianal Crohn's disease.
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Tu1807 - Genetically Distinct Signatures of Mild and Severe Ulcerative Colitis
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Tu1807 - Genetically Distinct Signatures of Mild and Severe Ulcerative Colitis
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Mo1879 - Vedolizumab(VDZ) Real World Outcomes in Ulcerative Colitis (UC)
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Mo1879 - Vedolizumab(VDZ) Real World Outcomes in Ulcerative Colitis (UC)
- Open Access
- 29 August 2017
- Published by Springer Nature in BMC Medical Genetics
- Vol. 18 (1) , 1-11
Performance of risk prediction for inflammatory bowel disease based on genotyping platform and genomic risk score method
Predicting risk of disease from genotypes is being increasingly proposed for a variety of diagnostic and prognostic purposes. Genome-wide association studies (GWAS) have identified a large number of genome-wide significant susceptibility loci for Crohn’s disease (CD) and ulcerative colitis (UC), two subtypes of inflammatory bowel disease (IBD). Recent studies have demonstrated that including only loci that are significantly associated with disease in the prediction model has low predictive power and that power can substantially be improved using a polygenic approach. We performed a comprehensive analysis of risk prediction models using large case-control cohorts genotyped for 909,763 GWAS SNPs or 123,437 SNPs on the custom designed Immunochip using four prediction methods (polygenic score, best linear genomic prediction, elastic-net regularization and a Bayesian mixture model). We used the area under the curve (AUC) to assess prediction performance for discovery populations with different sample sizes and number of SNPs within cross-validation. On average, the Bayesian mixture approach had the best prediction performance. Using cross-validation we found little differences in prediction performance between GWAS and Immunochip, despite the GWAS array providing a 10 times larger effective genome-wide coverage. The prediction performance using Immunochip is largely due to the power of the initial GWAS for its marker selection and its low cost that enabled larger sample sizes. The predictive ability of the genomic risk score based on Immunochip was replicated in external data, with AUC of 0.75 for CD and 0.70 for UC. CD patients with higher risk scores demonstrated clinical characteristics typically associated with a more severe disease course including ileal location and earlier age at diagnosis. Our analyses demonstrate that the power of genomic risk prediction for IBD is mainly due to strongly associated SNPs with considerable effect sizes. Additional SNPs that are only tagged by high-density GWAS arrays and low or rare-variants over-represented in the high-density region on the Immunochip contribute little to prediction accuracy. Although a quantitative assessment of IBD risk for an individual is not currently possible, we show sufficient power of genomic risk scores to stratify IBD risk among individuals at diagnosis.
- 29 August 2017
- Published by Springer Nature in BMC Medical Genetics
- Vol. 18 (1) , 1-11
Open AccessPerformance of risk prediction for inflammatory bowel disease based on genotyping platform and genomic risk score method
Predicting risk of disease from genotypes is being increasingly proposed for a variety of diagnostic and prognostic purposes. Genome-wide association studies (GWAS) have identified a large number of genome-wide significant susceptibility loci for Crohn’s disease (CD) and ulcerative colitis (UC), two subtypes of inflammatory bowel disease (IBD). Recent studies have demonstrated that including only loci that are significantly associated with disease in the prediction model has low predictive power and that power can substantially be improved using a polygenic approach. We performed a comprehensive analysis of risk prediction models using large case-control cohorts genotyped for 909,763 GWAS SNPs or 123,437 SNPs on the custom designed Immunochip using four prediction methods (polygenic score, best linear genomic prediction, elastic-net regularization and a Bayesian mixture model). We used the area under the curve (AUC) to assess prediction performance for discovery populations with different sample sizes and number of SNPs within cross-validation. On average, the Bayesian mixture approach had the best prediction performance. Using cross-validation we found little differences in prediction performance between GWAS and Immunochip, despite the GWAS array providing a 10 times larger effective genome-wide coverage. The prediction performance using Immunochip is largely due to the power of the initial GWAS for its marker selection and its low cost that enabled larger sample sizes. The predictive ability of the genomic risk score based on Immunochip was replicated in external data, with AUC of 0.75 for CD and 0.70 for UC. CD patients with higher risk scores demonstrated clinical characteristics typically associated with a more severe disease course including ileal location and earlier age at diagnosis. Our analyses demonstrate that the power of genomic risk prediction for IBD is mainly due to strongly associated SNPs with considerable effect sizes. Additional SNPs that are only tagged by high-density GWAS arrays and low or rare-variants over-represented in the high-density region on the Immunochip contribute little to prediction accuracy. Although a quantitative assessment of IBD risk for an individual is not currently possible, we show sufficient power of genomic risk scores to stratify IBD risk among individuals at diagnosis.
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
1161 Adalimumab Prevents Post-Operative Crohn's Disease Recurrence, and is Superior to Thiopurines: Early Results From the POCER Study
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
1161 Adalimumab Prevents Post-Operative Crohn's Disease Recurrence, and is Superior to Thiopurines: Early Results From the POCER Study